# Mirion Technologies, Inc. (MIR)

> Source: Nexqual · https://nexqual.com/MIR · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Mirion Technologies, Inc. (MIR), nexqual.com/MIR" · informational, not investment advice.

**Price:** USD 14.92 (-2.93% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 15.37 · day 14.65–15.09 · 52w 14.04–30.28 · market cap $3.72B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.02B, net income $24.5M (2.4% margin), free cash flow $134M (SEC filings).
- Valuation: P/E 151.7x (avg 212.4x at the last 1 fiscal year-ends), EV/EBITDA 18.3x, net debt $26.6M.
- 2 of 80 tracked superinvestors hold MIR (13F, Q2 2026): 0 new, 1 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $165K; 1 not under a Rule 10b5-1 plan ($165K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $312K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.91 on a 1–5 scale) (11 analysts), mean target USD 24 (range 20–29).
- Total return with dividends: 1Y -37.9% vs S&P 500 +14.9%; 5Y +38.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 0.12, revenue estimate $275M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $718M | $801M | $861M | $925M | $1.02B |
| Gross profit | — | $310M | $356M | $400M | $439M | — |
| Operating income | — | -$298M | -$21.9M | $24.8M | $51.5M | $54.5M |
| Net income | -$158M | -$277M | -$96.9M | -$36.1M | $28.8M | $24.5M |
| EPS (diluted) | — | -$1.53 | -$0.49 | -$0.18 | $0.11 | — |
| Free cash flow | — | $5.2M | $58.1M | $50.3M | $107M | $134M |
| Gross margin | — | 43.2% | 44.5% | 46.4% | 47.4% | — |
| Operating margin | — | -41.5% | -2.7% | 2.9% | 5.6% | 5.3% |
| Net margin | — | -38.6% | -12.1% | -4.2% | 3.1% | 2.4% |
| Revenue growth | — | — | +11.6% | +7.5% | +7.5% | — |
| Cash + short-term investments | $84.0M | $73.5M | $129M | $175M | $412M | — |
| Total debt | $811M | $807M | $686M | $686M | $445M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 151.7x · P/S 3.6x · EV/EBITDA 18.3x · EV/Sales 3.6x · P/FCF 27.8x · P/B 2.0x · FCF yield 3.60% · Earnings yield 0.66% · Buyback yield (TTM) 1.10% · Net debt $26.6M · EV $3.74B
P/E at fiscal year-ends: Dec 2025 212.4x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold MIR. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Leon Cooperman | Omega Family Office | 4.24% | $150M | Unchanged |
| Lee Ainslie | Maverick Capital | 0.85% | $94.0M | Added +97.9% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-07 | Moore Christopher A. | Chief Accounting Officer (PAO) | 8,400 | $165K | 27.5% | No | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $312K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-02 | Schopfer Brian | Chief Financial Officer | 20,000 | $312K | 15.6 | Too little history (no open-market trades in 2023) |

## Analysts
Consensus Buy (mean 1.91 on a 1–5 scale), 11 analysts; mean target USD 24 (low 20, high 29).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-03 | Jefferies | Initiated | Buy | $20 |
| 2026-07-30 | Citigroup | Target lowered | Buy | $28 → $24 |
| 2026-07-30 | B. Riley Securities | Target lowered | Buy | $29 → $27 |
| 2026-07-13 | Morgan Stanley | Target lowered | Equal-Weight | $27 → $25 |
| 2026-07-10 | Goldman Sachs | Target lowered | Buy | $28 → $25 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -37.9% | +38.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -38.0% | +6.7% |
| Volatility (annualized) | 53.4% | 46.4% |
| Max drawdown | -52.5% (Oct 2025→Sep 2026) | -51.0% (Oct 2025→Aug 2026) |

## Peers (Specialty Industrial Machinery)
CR (Crane Company) USD 189.05 -7.52% · GNRC (Generac Holdlings Inc.) USD 188.02 -7.44% · GGG (Graco Inc.) USD 69.28 -15.32% · INIO (INNIO N.V.) USD 15.11 -10.43% · WTS (Watts Water Technologies, Inc.) USD 356.94 -1.78% · IEX (IDEX Corporation) USD 226.88 -3.63%

## More
Full page: https://nexqual.com/MIR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Nuclear & Safety | $186.2M | 69.8% | +31.4% |
| Medical | $80.6M | 30.2% | -0.7% |
| Total revenue | $266.8M | 100% | — |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Product | $204.3M | 76.6% | +24.4% |
| — Nuclear Power (part of Product) | $118.1M | 44.3% | +43.8% |
| — Other Research (part of Product) | $39.0M | 14.6% | +21.1% |
| — Labs & Research (part of Product) | $29.1M | 10.9% | +6.2% |
| — Other Care (part of Product) | $17.8M | 6.7% | -6.3% |
| Cancer Care | $62.8M | 23.5% | +1.0% |
| Service | $62.5M | 23.4% | +6.5% |
| Total revenue | $266.8M | 100% | — |
The lines above cover 123.5% of total revenue.

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| North America | $179.1M | 67.1% | +28.9% |
| Europe | $85.1M | 31.9% | +4.0% |
| Asia Pacific | $2.6M | 1.0% | +18.2% |
| Total revenue | $266.8M | 100% | — |

## Company outlook (8-K filed 2026-07-28)

- "Commenting on Mirion's full year 2026 guidance, Logan said, "We remain well-positioned for second half 2026 accelerated revenue growth, adjusted free cash flow, and margin expansion."
- "Exhibit 99.1 News Release Additional modeling and guidance assumptions are included in the appendix of the earnings presentation on the Company's investor relations page."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.12 | $0.12 | -1.9% | $274.9M | 9 |
| Next quarter (ends 2026-12-31) | $0.21 | $0.21 | +1.4% | $340.1M | 9 |
| Current fiscal year (ends 2026-12-31) | $0.55 | $0.53 | +2.9% | $1.14B | 9 |
| Next fiscal year (ends 2027-12-31) | $0.67 | $0.65 | +3.2% | $1.22B | 8 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-10-27): ±15.8%; last 8 reports averaged ±8.6%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 70.0% | ±15.8% |
| 2026-12-18 | 56 | 60.1% | ±18.9% |
| 2027-01-15 | 84 | 57.5% | ±22.1% |
| 2027-02-19 | 119 | 57.4% | ±26.1% |
| 2027-05-21 | 210 | 56.8% | ±34.3% |